Collagen fragment‑integrin signaling epigenetically silences HAS2 in aged fibroblasts, independent of ERK suppression

Hypothesis

Age‑related accumulation of collagen fragments not only reduces nuclear phospho‑ERK1/2 but also engages integrin α2β1 to recruit histone deacetylase 2 (HDAC2) to the HAS2 promoter, causing sustained transcriptional repression that persists even when ERK activity is restored.

Mechanistic Rationale

Collagen fragments generated by MMPs expose cryptic RGD‑like motifs that bind integrin α2β1 on fibroblasts (see [1] for MMP‑collagen fragment link). Integrin activation triggers focal adhesion kinase (FAK)–Src signaling, which can phosphorylate and activate HDAC2, promoting its translocation to the nucleus. HDAC2 deacetylates histone H3 lysine 9 at the HAS2 promoter, compacting chromatin and blocking transcription factor access, notably ELK‑1 and SP1. This epigenetic lock maintains low HAS2 mRNA despite intermittent ERK reactivation, explaining why transient antioxidant or MAPK rescue experiments fail to fully restore HA synthesis in aged dermis.

In parallel, collagen fragment‑integrin signaling sustains a senescent-associated secretory phenotype (SASP) via NF‑κB activation downstream of FAK‑Src, reinforcing the feedforward loop: SASP cytokines further upregulate MMPs, producing more fragments. The hypothesis predicts that HDAC2 recruitment is size‑specific: fragments <200 nm (≈<50 kDa collagen peptides) efficiently engage α2β1, whereas larger fibrillar collagen does not.

Testable Predictions

1. Integrin blockade – Treating senescent dermal fibroblasts with function‑blocking α2β1 antibody or small‑molecule inhibitor (e.g., ATN‑161) will increase HAS2 transcription and HMW‑HA secretion even when ERK phosphorylation remains low.
2. HDAC2 dependency – siRNA knockdown of HDAC2 or pharmacological inhibition (e.g., caustic acid) will rescue HAS2 expression and reduce LMW‑HA‑induced NF‑κB activity, whereas HDAC1 knockdown will not.
3. Chromatin changes – ChIP‑qPCR will show increased HDAC2 occupancy and decreased H3K9ac at the HAS2 promoter in fragment‑treated cells, reversible by integrin blockade.
4. Size specificity – Synthetic collagen peptides of defined lengths (<50 kDa vs. >150 kDa) will differentially affect α2β1‑FAK‑HDAC2 signaling and HAS2 repression, with only the smaller peptides causing sustained suppression.

Falsifiability

If integrin α2β1 inhibition fails to restore HAS2 mRNA or HA synthesis under conditions of confirmed collagen fragment presence, or if HDAC2 knockdown does not alter promoter acetylation or HAS2 output, the hypothesis is refuted. Conversely, demonstration that ERK reactivation alone restores HAS2 despite persistent integrin‑HDAC2 signaling would also falsify the proposed epigenetic dominance.

Broader Implications

Validating this mechanism would reveal a transcription‑independent, ECM‑driven layer of age‑related HAS2 suppression, suggesting that therapeutic strategies targeting integrin‑HDAC2 signaling (rather than solely MAPK or oxidative pathways) could more effectively restore HA homeostasis in aging skin and joint tissues.